ReviewNutrients2026
GLP-1 Receptor Agonists, Gut Microbiota, and Chronic Pain: Nutritional Signaling at the Gut-Brain Axis.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesChronic pain affects more than one in five adults worldwide and is increasingly conceptualized as a disorder of the gut-brain axis. Gut microbial dysbiosis, characterized by reduced alpha-diversity and depletion of short-chain fatty acid (SCFA)-producing taxa such as
methodsWe conducted a narrative synthesis of studies retrieved from PubMed, Embase, and Web of Science from inception through 30 June 2026, spanning GLP-1 nutrient sensing, gut microbial alterations in pain, GLP-1RA effects on the microbiome, microbiota-dependent mechanisms, and clinical pain outcomes.
resultsGLP-1 is secreted by L-cells in response to nutrients and microbial SCFAs, signaling to the brain through vagal and humoral routes. GLP-1RAs enrich the same anti-inflammatory, SCFA-producing taxa that are depleted in chronic pain, and their anti-inflammatory actions require an intact microbiota. Mechanistically, GLP-1RAs suppress pain through spinal microglial GLP-1 receptor (GLP-1R)/interleukin-10/beta-endorphin signaling, Nucleotide-binding oligomerization domain (NOD)-, Leucine-rich repeat (LRR)-, and pyrin domain-containing protein 3 (NLRP3) inflammasome inhibition, and receptor-independent transient receptor potential vanilloid 1 (TRPV1) blockade, largely independent of glycemic control or weight loss. Clinically, evidence is strongest for knee osteoarthritis and idiopathic intracranial hypertension headache, with emerging signals in fibromyalgia, visceral pain, and reduced opioid use.
conclusionsThe gut microbiota is proposed to act as both a therapeutic target and a mechanistic intermediary in GLP-1RA-mediated analgesia, a model that awaits direct confirmation in humans. Pain-specific trials incorporating dietary and microbiome endpoints are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.